Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12952801 | 0.88 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1KDM4ETSHRTDP1 | |
| SCHEMBL1985337 | 0.87 | TUBB1 (0.51) | ALDH1A1L3MBTL1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3718733 | 0.87 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL20638988 | 0.83 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1CYP1A1CYP1B1KDM4E | |
| SCHEMBL22208757 | 0.83 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1CYP1A2KDM4ETSHR | |
| SCHEMBL96291 | 0.82 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1CYP1A1CYP1B1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9456784 | 0.80 | ALDH1A1 (0.96) | ALDH1A1L3MBTL1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL2001499 | 0.80 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL28328818 | 0.80 | LMNA (0.56) | ALDH1A1CYP1A2TSHRKMT2ALMNA | |
| SCHEMBL1221345 | 0.79 | GPR3 (0.41) | ALDH1A1CYP1A2TSHRTRIM24TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
| EP-3860984-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | disclosed |
| CN-112912371-A | Flavone derivatives for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020070088-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-09 | — | — | WO | disclosed |
| CN-105793238-B | Substituted benzamides and methods of use thereof | 基因泰克公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
| EP-2809671-B1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2809671-A1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cephalon, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
| US-8546376-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| WO-2013116291-A1 | IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | ALDH1A1 643/4885L3MBTL1 4391/4885CYP1A1 259/4885 |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | JAK1, ALK, JAK2 | ALDH1A1 653/4885L3MBTL1 3318/4885CYP1A1 1377/4885 |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | ALDH1A1 2392/4885L3MBTL1 4251/4885CYP1A1 1288/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | ALDH1A1 912/4885L3MBTL1 3583/4885CYP1A1 192/4885 |
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PLK1, MTOR | ALDH1A1 4088/4885L3MBTL1 4396/4885CYP1A1 4622/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | ALDH1A1 1306/4885L3MBTL1 3667/4885CYP1A1 478/4885 |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | CCNE2, CCNE1, CCNT1 | ALDH1A1 455/4885L3MBTL1 1655/4885CYP1A1 19/4885 |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | CCNE2, CCNE1, CCNT1 | ALDH1A1 455/4885L3MBTL1 1655/4885CYP1A1 19/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | ALDH1A1 912/4885L3MBTL1 3583/4885CYP1A1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.